Literature DB >> 15781001

Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.

Bo Abrahamsen1, Jacob Vb Hjelmborg, Paul Kostenuik, Lis S Stilgren, Kirsten Kyvik, Stephen Adamu, Kim Brixen, Bente L Langdahl.   

Abstract

UNLABELLED: Osteoprotegerin (OPG) is a circulating receptor that inhibits osteoclastogenesis by binding to RANK ligand (RANKL). OPG knock-out animals develop severe osteoporosis. Treatment with OPG lowers bone resorption and increases BMD. OPG production is influenced by a wide range of hormones and cytokines. The influence of genetic factors on circulating amounts of OPG and RANKL is not known. BMD has been demonstrated to have a high heritability and there is evidence also that bone turnover and bone loss rates are controlled at least in part by genetic factors.
OBJECTIVE: Assessing the genetic impact on serum OPG and RANKL in women and estimation of the relative contribution of this inheritance to the total heritability of BMD.
METHODS: 188 female twins (52 DZ and 42 MZ pairs) from the Danish Twin Registry were included in the study. Mean age was 35 years (range 19-64 years), average spine BMD was 1.04 +/- 0.11 g/cm2. Serum levels of OPG and RANKL were measured by ELISA (Biomedica, Vienna, Austria). This register covers twins born in Denmark since 1870. Heritability and environmental influence was assessed using a maximum-likelihood model for genetic pleiotropy.
RESULTS: RANKL levels showed a negative correlation with age and lower values in smokers. OPG levels were higher in postmenopausal women. Heritability (h(2)) was 85% for spine BMD and 52% for serum RANKL after adjustment for age, smoking and BMI. By contrast, there was no significant genetic influence on OPG levels (h(2) = 0, 95% CI: 0 to 0.31). Serum OPG was determined almost exclusively by individual environment (e(2) = 0.79), with a small, non-significant contribution from shared environment (c(2) = 0.21). Restricting analyses to the 158 premenopausal twins did not alter the findings.
CONCLUSIONS: Serum OPG and RANKL levels have only a weak relation to BMD in healthy women. Phenotype correlations indicate that the genes that contribute to twin similarity for BMD are not genes regulating serum levels of RANKL or OPG. The weak correlation with BMD appears to consist in shared environmental factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781001     DOI: 10.1016/j.bone.2004.12.015

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  18 in total

1.  Premenopausal Trabecular Bone Loss is Associated with a Family History of Fragility Fracture.

Authors:  J C Prior; C L Hitchcock; Y M Vigna; V Seifert-Klauss
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-08       Impact factor: 2.915

Review 2.  Relationship between serum RANKL and RANKL in bone.

Authors:  D M Findlay; G J Atkins
Journal:  Osteoporos Int       Date:  2011-08-18       Impact factor: 4.507

3.  Family resemblance of bone turnover rate in mothers and daughters--the MODAM study.

Authors:  H Nagy; R Chapurlat; E Sornay-Rendu; S Boutroy; P Szulc
Journal:  Osteoporos Int       Date:  2014-12-19       Impact factor: 4.507

4.  Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.

Authors:  L Jørgensen; A Vik; N Emaus; J Brox; J-B Hansen; E Mathiesen; P Vestergaard
Journal:  Osteoporos Int       Date:  2009-08-22       Impact factor: 4.507

5.  Meta-analysis of genome-wide association studies identifies two loci associated with circulating osteoprotegerin levels.

Authors:  Johnny S H Kwan; Yi-Hsiang Hsu; Ching-Lung Cheung; Josée Dupuis; Aude Saint-Pierre; Joel Eriksson; Samuel K Handelman; Aaron Aragaki; David Karasik; Peter P Pramstaller; Charles Kooperberg; Andrea Z Lacroix; Martin G Larson; Kam-Shing Lau; Mattias Lorentzon; Irene Pichler; Pak C Sham; Daniel Taliun; Liesbeth Vandenput; Douglas P Kiel; Andrew A Hicks; Rebecca D Jackson; Claes Ohlsson; Emelia J Benjamin; Annie W C Kung
Journal:  Hum Mol Genet       Date:  2014-07-30       Impact factor: 6.150

6.  Vitamin K, circulating cytokines, and bone mineral density in older men and women.

Authors:  M Kyla Shea; Gerard E Dallal; Bess Dawson-Hughes; José M Ordovas; Christopher J O'Donnell; Caren M Gundberg; James W Peterson; Sarah L Booth
Journal:  Am J Clin Nutr       Date:  2008-08       Impact factor: 7.045

7.  Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease.

Authors:  Y Y Yuan; P J Kostenuik; M S Ominsky; S Morony; S Adamu; D T Simionescu; D M Basalyga; F J Asuncion; T A Bateman
Journal:  Osteoporos Int       Date:  2007-11-24       Impact factor: 4.507

8.  Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women.

Authors:  H Uemura; T Yasui; Y Miyatani; M Yamada; M Hiyoshi; K Arisawa; M Irahara
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

9.  The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.

Authors:  Anna Stern; Gail A Laughlin; Jaclyn Bergstrom; Elizabeth Barrett-Connor
Journal:  Eur J Endocrinol       Date:  2007-05       Impact factor: 6.664

10.  OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.

Authors:  Andrea Z LaCroix; Rebecca D Jackson; Aaron Aragaki; Charles Kooperberg; Jane A Cauley; Zhao Chen; Meryl S Leboff; David Duggan; Jean Wactawski-Wende
Journal:  Bone       Date:  2013-06-02       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.